International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

Effective Strategies for Launching and Increasing the Sales of a New Drug

Deepesh Kumar and Sonali Gupta

Date of Submission: 01-08-2023 Date of Acceptance: 13-08-2023

ABSTRACT
The successful introduction and growth of a new drug in the market require a well-executed plan that encompasses several key elements. The pharmaceutical industry is highly competitive and launching a new drug successfully can be a challenging task. The objective of this report is to identify effective strategies for launching and increasing the sales of a new drug. The research methodology used in this study involved a comprehensive review of literature and analysis of case studies of successful drug launches. The findings of this study reveal that a successful drug launch requires a strategic approach that includes pre-launch activities, effective marketing strategies, and post-launch monitoring and evaluation.

Pre-launch activities include Market research, clinical trials and regulatory compliance. Effective marketing strategies involve Identifying the target audience, creating a compelling brand message and using a mix of promotional channels to reach customers. Post-launch monitoring and evaluation involve Tracking sales, assessing the impact of the drug on patients and making necessary adjustments to the marketing strategy.

Firstly, conducting thorough market research is crucial to identify the target audience and understand their needs, preferences, and treatment landscape. This information enables pharmaceutical companies to develop a tailored marketing and sales approach that resonates with healthcare providers and patients.

Secondly, positioning the new drug effectively is essential. Highlighting its unique features, benefits, and points of differentiation compared to existing treatments can help to create a compelling value proposition. Clear and impactful branding and messaging should be developed to communicate the drug's value to the target audience.

The results of this study can be used by pharmaceutical companies to develop effective launch strategies and increase their chances of success in a highly competitive market.

Keywords –New drug launch, Marketing, Market Research, Target Audience, Brand Message and Success Factors.

I. INTRODUCTION

New drugs, generally, imply better treatment of illnesses [4,5]. It is widely accepted that access to modern medical therapies has contributed immensely to the developmental catch-up process of many less developed countries [3]. A delay in the launch of new drugs, therefore, can prove detrimental to the economic development of a region or country. Motivated by this study, many other empirical studies were conducted to understand the dynamics of drug launch across countries. A strong focus of these studies was their use of comprehensive proprietary cross-country databases. However, one can identify two broad limitations to these studies.

In recent years, a number of studies have explored the dynamics of drug launch in developing countries. Broadening the sample and incorporating these countries enhances the scope of research in two ways. First, as mentioned above, being located in tropical regions, the disease pattern in these countries is quite different [13, 14]. The majority of the population in these countries suffer from communicable tropical diseases. Demand differences are thus a key verifiable determinant of the diffusion of new drugs in these countries. Secondly, until very recently, pharmaceutical markets in many of these countries were run under a weak patent system, which permitted reverse engineering and incremental innovations. Therefore, new drugs in these countries could be launched by any firm present in the market, and not only by the

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

innovating firm [15]. Issues like competitive pressure to launch, and first mover advantages can thus, also be incorporated into the analyses of drug launch [11,15].

INTRODUCTION PROCESS OF NEW DRUG:

1. DISCOVERY AND PATIENT FILLING
2. PRE-CLINICAL TRIALS
3. CLINICAL TRIALS
4. APPROVAL AND LAUNCH PREPARATIONS

FIG.1- Overview of the new product introduction process (inspired by FDA, 2004)

The new product introduction process is the process stretching from first discovery to market launch and covers developing, testing and manufacturing a new product (cf. Figure 1.2). After first discovery, patent is filed. Hereafter follow pre-clinical studies to test toxicity of the drug, before it is put into a series of human trials called the clinical trials. One set of clinical trials is enough for applying for approval with authorities in several countries, given that the trials comply with the standards set by each authority. Due to the cost and length of the trials, companies seek to do only one set to cover all markets.

Another regulatory task, which is often performed by different authorities, is giving the final market authorization after concluding the reimbursement negotiations with the companies. In these negotiations, maximum price and reimbursement level are settled. The negotiations are important as the reimbursement often covers most of the patients' expenses for the treatment and because many countries only allow drugs with such an authorization to be prescribed by general practitioners (Cook, 2006). Getting the market authorization is hence a perquisite for gaining any demand in the market.

DIFFERENT LAUNCHING PROCESS OF NEW DRUG:

Over the next three years, pharmaceutical companies will launch some 400 products and Finally, our research suggests that many upcoming product launches will need to be creative in crafting their value proposition and marketing claim. We recently analysed sample of 60 upcoming product launches according to two criteria: the product's perceived level of differentiation from existing treatments and the extent to which the target disease is perceived as a significant burden to society. (For instance, diabetes and cardiovascular diseases are a priority for healthcare institutions, but not everyone would agree on the urgency of treating ADHD.)

indications per year, up 146 percent from 2005. By 2015, sales from products launched in the past five years should account for more than US $80 billion worldwide.

In an era of patent cliffs and shrinking pipelines, capturing full value from every product launch is critical. But with only about a third of launches meeting or exceeding analysts' expectations, the challenge is considerable, and unlikely to get any easier. For one thing, there is no let-up in announcements of austerity plans affecting pharmaceuticals, and many markets are already implementing short- and long-term measures to reduce spending.

At the same time, launches are becoming smaller and more competitive. Portfolios are highly fragmented, with sales from the top 10 products in 2014 likely to be half those in 2008, and specialty launches accounting for 75 percent of pipeline drugs, up from 58 percent in 2004. In a world of mounting pressure on margins, growing complexity, and more targeted launches, companies face the question "How can we do more with less at launch?"

Our analysis revealed that just 25 percent of upcoming launches in the sample showed significant differentiation and treated a disease area

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

with a high perceived burden, while more than 53 percent showed moderate or no differentiation and will need to find a positioning edge to make them stand out from the crowd.

EFFECTS OF REGULATION ON DRUG LAUNCH AND PRICING:

New drugs are potentially global products and can contribute importantly to health outcomes for consumers and expenditures for payers. Prompt launch is also critical for drug manufacturers, given the fixed patent life over which to recoup the high costs of R&D.1 In fact, in a study of the 1990s launch experience of 85 drugs in 25 industrialized countries, roughly half of the potential country-compound launches occurred, and many of the eventual launches involved months or years of delay (Danzon, Wang, & Wang, 2005).

PRICE REGULATION MAY DELAY LAUNCH DIRECTLY THROUGH THREE MECHANISMS:

1. Regulation that reduces the manufacturer's expected price and net present value (NPV) of revenues reduces incentives for launch, especially in small countries and for drugs with low expected sales volume, assuming some fixed costs of launch.
2. Negotiation strategies may lead to strategic delay by firms or regulators to influence the ultimate price.
3. Regulatory processes may entail pure bureaucratic delay.

The welfare consequences of these direct/domestic effects of a country's regulation on its citizens are ambiguous a priori, because any foregone health benefit due to fewer/later launches may be offset by savings from lower drug prices and better pre-launch information about a drug's relative safety and effectiveness when one country regulates its drug price with reference to the price of the same drug in other countries (''external referencing''). For example, many EU countries cap their prices at the mean, median, or minimum price in a group of other EU countries. By under-mining market segmentation and price discrimination, external referencing by high-price countries creates spill over incentives for a firm to seek higher prices or not launch in lower-price referenced countries.

The welfare consequences in the referenced low-price countries are clearly negative, since they suffer reduced access to new drugs and possibly higher prices due to external referencing by other countries, with no offsetting benefits. Parallel importation by high-price EU countries from low-price EU countries is a second spill over mechanism that may also contribute to non-launch and higher prices, and hence negative welfare consequences for the exporting countries.

Understanding these indirect effects of one country's regulation on launch in other countries is particularly important as the scope of referencing is increasing in the EU and in other regions, and the United States considers both referencing foreign drug prices and/or legalizing parallel trade (''drug importation'').

THE INDIAN PHARMACEUTICAL INDUSTRY: A BIRD'S EYE ON VIEW:

Until the decade of the 1960s, the Indian pharmaceutical industry relied heavily on imports, while attempts were being made to develop production capabilities of important medicines in the country. Public sector firms like Hindustan Antibiotic Limited, and Indian Drugs and Pharmaceutical Limited were set up to facilitate this process with imported manufacturing and process technologies from the USSR. This report turned out to be a major game changer in policymaking, and various measures were initiated to control drug prices.

The relaxation of patent protection proved to be a boon to the industry. Armed with various other policies to reduce prices (Drug Price Control Orders or DPCO) and foreign competition, the domestic industry surged ahead with strengthening capacity to implement reverse engineering and process innovations.

Along with the change in the regulatory framework, the production structure of the industry also witnessed a change in direction in the mid-1990s. From an exclusive focus on chemical drugs, the industry started moving into the business of biopharmaceuticals. This development was not, however, an isolated development and during the same period, hundreds of biotechnology firms were also set up in the US and Europe. The majority of Indian biotechnology firms sprouted only in the early 1990s, largely as backyard firms churning out enzymes from fermentations.

Gradually, they moved to the manufacture of vaccines, and today Indian vaccine sales account for about 43 % of the country's total

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

biopharmaceutical sales, compared to 16 % for diagnostics and 13 % for therapeutics. India is one of the world's leading suppliers of vaccines for measles and other childhood vaccinations. This signifies that the current biopharma landscape is concentrated largely around vaccine synthesis and hence for this space to mature what is required is to diversify with respect to the biosimilars production.

BRIEF INTRODUCTION:

Launching and increasing sales of a new drug requires carefully planned and executed strategy that addresses several key factors. Here are some effective strategies for launching and increasing sales of a new drug:

1. CONDUCT MARKET RESEARCH: Before launching a new drug, it's important to understand the market landscape and your target audience. 4.ESTABLISH A STRONG ONLINE PRESENCE: Establishing a strong online presence is essential in today's digital world. Create a website, social media profiles and other channels that promote your drug, and engage with patients and healthcare professionals online.

5.PROVIDE EDUCATIONAL RESOURCES: Patients and healthcare professionals need to be educated about the benefits and risks of the new drug. Providing educational resources such as brochures, videos and webinars can help increase awareness and understanding of your drug.

6. OFFER PATIENT SUPPORT PROGRAMS: Patient support programs can help improve patient outcomes and increase patient loyalty. Programs such as co-pay assistance, nurse support, and

Market research can help you identify the unmet needs, competitor offerings, and the pricing of similar drugs.

2. DEVELOP A COMPREHENSIVE MARKETING PLAN: A comprehensive marketing plan should be developed that outlines the key messages, target audience, channels for promotion and timelines for execution. The plan should also include strategies for engaging with healthcare professionals as well as patients and care givers.

3.LEVERAGE KEY OPINION LEADERS: Key Opinion Leaders (KOLs) are healthcare professionals who have a significant influence on the prescribing habits of their peers. Engaging with KOLs on can help build credibility and awareness for your drug.

disease management can help patients access and adhere to the new drug.

7. MEASURE AND OPTIMIZE: Measuring the effectiveness of your launch strategy is critical to optimizing future efforts. Collect and analyse data on sales, customer feedback and campaign metrics to identify areas for improvement and make data-driven decisions.

The process of launching and increasing sales of a new drug can be a complex and challenging task for pharmaceutical companies. A successful drug launch requires a coordinated effort that involves a range of stakeholders including marketing teams, sales representatives, healthcare professionals, patients and care givers.

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

OBJECTIVES

Launching a new drug can be a complex and challenging process, and there are many strategies that can be used to increase its sales. Here are some objectives that can guide an effective launch strategy:

1.CREATE AWARENESS: The first objective of launching a new drug is to create awareness among healthcare professionals, patients, and the general public. This can be achieved through various channels such as advertising, public relations, digital marketing, conferences, and medical education programs.

2. BUILD CREDIBILITY: It is important to build credibility and trust among the target audience by providing accurate and reliable information about the drug. This can be achieved through scientific publications, clinical trial data, endorsements from key opinion leaders, and patient testimonials.

3. TARGET THE RIGHT AUDIENCE: It is important to target the right audience will the right message. This involves identifying the patient population that will benefit most from the drug, as well as the healthcare professionals who are most likely to prescribe it.

4. DIFFERENTIATE FROM COMPETITORS: In a crowded market, it is important to differentiate the new drug from its competitors. This can be achieved by highlighting its unique features, such as its mechanism of action, safety profile, or dosing regimen.

5. PROVIDE ACCESS: Access to the drug is essential for its success. This involves working with payers, pharmacies, and healthcare providers to ensure that the drug is available and affordable for patients.

6. MEASURE SUCCESS: It is important to measure the success of the launch strategy and adjust it as needed. This involves tracking key metrics such as sales, market share, and customer satisfaction, and using this information to optimize the strategy going forward.

SCOPE

The scope of effective strategies for launching and increasing the sales of a new drug is wide-ranging and involves several key components. These strategies aim to create awareness, interest and demand for the new drug among the target audience. Some of the key components of an effective strategy for launching and increasing the sales of a new drug include:

1. MARKET RESEARCH AND ANALYSIS: Conducting market research and analysis to understand the needs and preferences of the target audience, the competition, and the market trends. This helps in developing an effective strategy that resonates with the target audience and differentiates the new drug from the competition.

2. PRODUCT POSITIONING: Developing a clear and compelling positioning strategy for the new drug that communicates its unique value proposition and benefits to the target audience. This helps to differentiate the new drug from the competition and increase its appeal to the target audience.

3. PRICING AND PROMOTIONAL TACTICS: Developing pricing and promotional tactics that effectively communicate the value and benefits of the new drug to the target audience. This may include discounts, rebates, coupons and other incentives that encourage customers to try the new drug.

4. SALES FORCE TRAINING AND MANAGEMENT: Providing comprehensive training to the sales force to equip them with the knowledge and skills they need to effectively promote the new drug to physicians and other key decision-makers in the healthcare industry.

5.ONGOING POST-LAUNCH MONITORING AND EVALUATION: Continuously monitoring and evaluating the performance of the new drug and its impact on the market. This helps in identifying the opportunities for improvement and optimizing the launch strategy to maximize its effectiveness.

6. PARTNERSHIPS AND COLLABORATIONS: Forming partnerships and collaborations with other companies, organizations and key opinion leaders to expand the reach and visibility of the new drug and increase its appeal to the target audience.

7. DIGITAL MARKETING AND SOCIAL MEDIA: Leveraging digital marketing and social

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

media channels to engage with the target audience in new and innovative ways such as creating educational content, hosting webinars and building online communities.

8. DEVELOP A STRONG BRAND IDENTIFICATION: Building a strong brand identity is essential for any new drug. This includes creating a memorable name and logo, developing a clear brand message, and establishing a visual identity that resonates with the target audience.

9. LEVERAGE KEY OPINION LEADERS: Identifying and engaging with key opinion leaders (KOLs) in the medical community can help increase awareness and credibility for a new drug. KOLs can provide expert opinion and help promote the drug to other healthcare professionals.

10. UTILIZE TARGETED ADVERTISING: Advertising can be an effective way to reach potential customers and increase sales. However, it's important to target advertising to the right audience using channels that are likely to be effective.

11. PROVIDE EDUCATION AND SUPPORT: Educating healthcare professionals and patients about the benefits of a new drug and providing ongoing support can help in increase adoption and adherence. This may include providing training materials, patient education materials and access to support services.

12. MONITOR AND ADJUST: Finally, it's important to continually monitor sales and adjust strategies as needed. This may include changing pricing, adjusting advertising tactics, or revising product messaging based on customer feedback.

LIMITATIONS

There are several limitations that can impact on the effectiveness of strategies for launching and increasing the sales of a new drug. Some of these limitations include:

1. REGULATORY CONSTRAINTS: The pharmaceutical industry is heavily regulated and any new drug must meet stringent regulatory requirements before it can be approved for sale. This can create delays in the launch of the drug, which can impact its effectiveness.

2. LIMITED MARKETING BUDGETS: Launching and promoting a new drug can be expensive and many pharmaceutical companies have limited budgets for marketing and advertising. This can limit the effectiveness of promotional activities and make it difficult to reach the intended target audience.

3. COMPETITION: The pharmaceutical industry is highly competitive and there may be many existing products on the market that are similar to the new drug. This can make it difficult to differentiate the new product and convince customers to switch to it.

4. LIMITED ACCESS TO DECISION-MAKERS: In the healthcare industry, decisions about which drugs to prescribe are often made by physicians, who may be difficult to reach or convince to switch to a new drug. This can limit the effectiveness of promotional activities and make it difficult to increase sales.

5. COMMUNICATION CHALLENGES: Communicating the value and benefits of a new drug can be challenging, especially if the drug is complex or has a narrow target audience. This can limit the effectiveness of promotional activities and make it difficult to increase sales.

6. UNFORESEEN FACTORS: Finally, there may be unforeseen factory that can impact the success of a new drug launch strategy, such as unexpected adverse effects or negative media coverage. These can damage the reputation of the drug and make it difficult to increase sales.

II. OVERVIEW OF PHARMACEUTICAL INDUSTRY

1. PRE-LAUNCH ACTIVITIES
2. NEW DRUG LAUNCH PROCESS
3. POST-LAUNCH MONITORING AND EVALUATION
4. MARKETING STRATEGIES

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494



FIG.2: OVERVIEW OF A PHARMACEUTICAL INDUSTRY

PRE-LAUNCH ACTIVITIES

The pre-launch activities of new drugs refer to the various activities and strategies that pharmaceutical companies undertake to prepare for the launch of a new drug in the market. These activities typically begin months or even years before the drug is launched and involve various stakeholders including regulatory agencies, healthcare providers, patients and payers.



FIG.3: OVERVIEW OF THE OPERATIONS LEADING UPTO AND DURING THE PRE-MARKET LAUNCH IN THE PHARMACEUTICAL INDUSTRY

SOME OF THE KEY PRE-LAUNCH ACTIVITIES OF NEW DRUGS INCLUDE:

1.REGULATORY APPROVAL:

(a) PRE-CLINICAL STUDIES: Before a new drug can be tested in humans, it must undergo pre-clinical studies to determine its safety and efficacy. It involves laboratory and animal studies to test the drug's effects on cells, tissues and organs.

(b) CLINICAL TRIALS: Once the drug has been tested in pre-clinical studies and deemed safe, it can move on to clinical trials. They involve testing the drug in humans to assess its safety and efficacy. It involves phase-1, phase-2 and phase-3 trials.

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

(c) SUBMISSION TO REGULATORY AUTHORITIES: It includes data from pre-clinical studies and clinical trials, as well as information about the drug's manufacturing, packaging and labelling.

(d) REVIEW AND APPROVAL: The review process can take several months or even years, depending on the complexity of the data and the drug's potential risks and benefits. If the drug is approved, the regulatory authority will issue a marketing authorization which allows the pharmaceutical company to market and sell the drug.

2. MARKET RESEARCH:

(a) DEFINE THE RESEARCH OBJECTIVES: The first step is to define the objectives of the research. This involves identifying the key questions that the research aims to answer, such as the potential market size, target audience, and the most effective marketing channels.

3.PRICING AND REIMBURSEMENT:

(a) EVALUATE THE MARKET: Pharmaceutical companies need to evaluate the market demand for the new drug and assess the competition to determine a price that is competitive yet profitable.

(b) DETERMINE THE VALUE OF THE DRUG: Pharmaceutical companies must assess the clinical and economic value of the new drug to determine a price that is in line with its value.

(c) DEFINE THE TARGET POPULATION: The pricing strategy may vary depending on these factors.

4. MARKETING AND PROMOTION:

(a) DEVELOP A MARKETING PLAN: It includes key objectives, target audience, messaging and tactics for promoting the new drug.

(b) MANUFACTURING: The drug is manufactured in accordance with regulatory standards and quality control measures.

(c) PACKAGING AND LABELLING: This includes proper dosage information, warnings and instructions for use.

(d) DISTRIBUTION NETWORK: It includes wholesalers, distributors and logistics providers.

(b) IDENTIFY THE TARKET AUDIENCE: This includes both healthcare professionals who will be prescribing the drug and patients who will be using it.

(c) DESIGN THE RESEARCH METHODOLOGY: There are various research methods that can be used to collect data, including surveys, focus groups, interviews, and observational studies.

(d) COLLECT DATA: Data can be collected from a variety of sources, including primary research (such as surveys and interviews) and secondary research (such as market reports and competitor analysis).

(e) ANALYZE THE DATA: The data collected needs to be analysed to identify trends, patterns, and insights. This can be done using statistical analysis software, such as SPSS or SAS.

(b) CONDUCT MARKET RESEARCH: It includes focus groups, surveys and other research methods.

(c) IDENTIFY KEY OPINION LEADERS: To help build awareness& credibility for new drug.

(d) SELECT PROMOTION CHANNELS: It include medical conferences, social media, digital advertising and other channels.

(e) IMPLEMENT MARKET PLAN: It involve adjusting tactics or messages based on market data and feedback.

5. DISTRIBUTION AND SUPPLY CHAIN MANAGEMENT:

(a) PRE-LAUNCH PLANNING: This includes determining the target market, estimating demand and forecasting the necessary inventory levels.

(e) ORDER FULFILLMENT: Orders are processed and the products are prepared for shipment.

(f) SHIPMENT AND LOGISTICS: The drug is transported from distribution centres to various points of care including hospitals, clinics, pharmacies and other healthcare facilities.

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

6. KEY OPINION LEADER (KOL) ENGAGEMENT:

(a) IDENTIFICATION OF KOLs: This process may involve reviewing scientific publications, attending medical conferences and seeking recommendations from experts in the field.

(b) ESTABLISHING RELATIONSHIPS: This can be done through direct communication, personal meetings, participation in advisory boards, or invitations to educational events or sponsored conferences.

(b) REGULATORY APPROVAL: Before initiating clinical trials, pharmaceutical companies must obtain approval from regulatory authorities such as the FDA.

(c) KEY OPINION LEADER ADVOCACY: It can occur through participation in conferences, publishing scientific articles or delivering presentations at scientific meetings.

(d) KOL FEEDBACK AND INPUT: It include clinical trial design, labelling, educational materials and market access strategies.

7. CLINICAL TRIALS:

(a) STUDY DESIGN: It includes defining the study population, randomization, blinding and selection of appropriate endpoints and outcome measures.

(c) PHASES OF CLINICAL TRIALS: Phase-I, Phase-II, Phase-III and Phase-IV trials.



FIG.4: CLINICAL TRIALS TO BE CONDUCTED IN PRE-LAUNCH ACTIVITIES

8. POST-MARKETING SURVEILLANCE:

(a) PURPOSE: It monitors the drug's safety and effectiveness in real world clinical practice.

(b) ADVERSE EVENT REPORTING: These reports are submitted to regulatory authorities such as FDA through systems like the Adverse Event Monitoring System (AERS).

(c) LABELLING UPDATES: Based on the findings from post-marketing surveillance, pharmaceutical companies may update the drug's labelling to include new safety information, contraindications, warnings, or precautions.

(d) SIGNAL DETECTION AND ASSESSMENT: Regulatory authorities and pharmaceutical companies analyse the reported adverse events and continuously monitor safety data to identify potential safety signals.

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

PROCESS OF LAUNCHING A NEW DRUG

The process of launching a new drug involves several stages and regulatory requirements to ensure its safety, efficacy, and proper marketing. While the specifics may vary between countries, here is a general overview of the typical drug launch process:

1.PRE-CLINICAL RESEARCH:

It is the initial stage of the drug development process that occurs before testing the drug on humans. It involves laboratory and animal studies to assess the drug's safety, dosage, potential effectiveness, and overall viability as a potential therapeutic agent.

(a) TARGET IDENTIFICATION AND VALIDATION: To identify a specific target such as a protein or enzyme, that plays a crucial role in a disease process. Once a target is identified, its validation is performed to confirm its relevance to the disease and its potential as a therapeutic agent.

(b) IN-VITRO STUDIES: These studies involve testing the drug candidate in controlled laboratory conditions using cells or tissues.

(a) PREPARING THE IND APPLICATION: This includes data from pre-clinical studies, such as in-vitro and animal studies as well as details about the drug's chemical composition, formulation and manufacturing processes.

(b) INVESTIGATIONAL PLAN: It includes information on the study design, objectives, target patient population, dosage regimen, duration of treatment, and endpoints to be evaluated.

(c) PRE-CLINICAL DATA: This includes data on the drug's pharmacology, pharmacokinetics and toxicology.

(d) MANUFACTURING INFORMATION: It ensures that the drug is manufactured consistently, maintaining its identity, purity, potency and stability.

(e) IND APPLICATION SUBMISSION: It includes all the relevant documents, data and supporting information as per the regulatory requirements.

(c) PHARMACOKINETICS AND PHARMACODYNAMICS: These studies provide critical information on dosage, frequency of administration, and potential interactions with other drugs.

(d) ANIMAL STUDIES: Conducted to evaluate the drug's safety, efficacy and potential toxicities in a living organism.

(e) FORMULATION DEVELOPMENT: It ensures that the drug is stable, easily administered, and can reach its target site effectively.

2. INVESTIGATIONAL NEW DRUG (IND) APPLICATION:

It provides comprehensive data and information about the drug candidate, its pre-clinical studies, manufacturing details and proposed clinical trial plans.

3.CLINICAL TRIALS:

The investigational drug is tested on human subjects to assess its safety, efficacy, dosage and potential side effects.

(a) PHASE-I CLINICAL TRIALS: They focus on evaluating the safety, dosage and tolerability of the investigational drug in a small group of healthy volunteers.

(b) PHASE-II CLINICAL TRIALS: They focus on further evaluating the drug's efficacy and side effects in a larger group of patients with the target disease or condition.

(c) PHASE-III CLINICAL TRIALS: These are larger-scale studies that aim to confirm the drug's efficacy, monitor side effects, and establish its overall risk-benefit profile.

4. NEW DRUG APPLICATION (NDA) SUBMISSION:

(a) Once the Phase-III trials are successfully completed and demonstrate positive results, the pharmaceutical company compiles the data and submits an NDA to the regulatory authority such as the Food and Drug Administration (FDA) in the United States.

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

(b) NDA includes comprehensive data from pre-clinical studies, clinical trials, manufacturing details, labelling and proposed use of the drug.

5. REVIEW AND APPROVAL:
(a) The regulatory authority thoroughly reviews the NDA to evaluate the drug's safety, efficacy, manufacturing quality, and proposed labelling. This review process ensures that the benefits of the drug outweigh its potential risks.

(b) The regulatory authority may request additional information or clarification during the review process.
(c) If the drug receives approval, it can be marketed and made available to patients.

6. MARKETING AND DISTRIBUTION:
(a) MARKETING STRATEGY DEVELOPMENT: Pharmaceutical companies develop a comprehensive strategy to effectively position and promote the new drug in the market.

(b) PROMOTIONAL MATERIAL DEVELOPMENT: This includes brochures, detailing aids, websites, digital content, advertisements, scientific publications, and press releases.

(c) DIRECT-TO-CONSUMER MARKETING: It involves advertising and promotional activities targeted at patients and the general public.

(d) KEY OPINION LEADER ENGAGEMENT: KOLs provide insights, endorse the drug, and participate in educational activities, conferences and advisory boards.

POST-LAUNCH MONITORING AND EVALUATION

Post-launch monitoring and evaluation of a new drug is an essential process to ensure its safety, efficacy, and overall performance in real-world conditions. It involves collecting and analysing data related to the drug's usage, adverse events, effectiveness, and any other relevant factors. Here are the key aspects of post-launch monitoring and evaluation:

1.PHARMACOVIGILANCE:
Pharmacovigilance is a critical component of post-launch monitoring for drugs. It involves the continuous monitoring, assessment, and management of the safety profile of a drug throughout its lifecycle.

(a) ADVERSE EVENT REPORTING: Healthcare professionals, patients, caregivers, and other stakeholders are encouraged to report any suspected AEs to regulatory authorities, pharmaceutical companies, or designated reporting systems.

(b) SIGNAL DETECTION: These signals help to guide further investigation and risk assessment.
(b) RISK MINIMIZATION STRATEGIES: These may include specific prescribing guidelines, recommended monitoring parameters, patient education materials, contraindications, warnings, precautions, and other risk mitigation measures.

(c) LABELLING UPDATES: They involve modifying the drug's package insert or prescribing information to include new safety information, warnings, precautions, contraindications, and other relevant details.

(c) RISK ASESSMENT AND EVALUATION: Once a safety signal is detected, a thorough risk assessment is conducted to evaluate the severity, frequency, and potential impact of the identified safety concern.

(d) BENEFIT-RISK ASSESSMENT: If the benefits of the drug are determined to outweigh the identified risks, risk management strategies are developed and implemented.

(e) POST-APPROVAL STUDIES: These studies can include large-scale observational studies, registries, or post-authorization safety studies (PASS).

2. RISK MANAGEMENT AND LABELLING UPDATES:
(a) RISK ASSESSMENT: Aims to determine the severity, frequency, and potential impact od identified risks and to understand the underlying mechanisms or contributing factors.

(d) REGULATORY REPORTING: Pharmaceutical companies are required to report any new safety information, including adverse events, to the

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

regulatory authorities as per regulatory guidelines and timelines.

(e) POST-MARKETING STUDIES: Including post-approval commitments and post-authorization safety studies (PASS), are often conducted to further evaluate the drug's safety and effectiveness in real-world settings.

(f) PHARMACOVIGILANCE SYSTEMS: They involve robust processes for collecting, analysing and reporting adverse event data.

3. PHARMACOEPIDEMIOLOGICAL STUDIES:

(a) STUDY DESIGN: Include cohort studies, case-control studies, and self-controlled designs.

(e) OUTCOME ASSESSMENT: Include clinical outcomes, safety end points, healthcare resource utilization, and health-related quality of life.

(f) COMPARATIVE EFFECTIVENESS: To evaluate how the new drug performs compared to other treatments or standard of care.

4. REGULATORY COMPLIANCE:

(a) ADVERSE EVENT REPORTING: It involves collecting, evaluating, and submitting reports of adverse events to regulatory authorities as per their guidelines and timelines.

(b) LABELLING UPDATES: These updates are made in collaboration with regulatory authorities to ensure accurate and up-to-date information for healthcare professionals and patients.

(c) POST-MARKETING SURVEILLANCE STUDIES: Pharmaceutical companies may be required to conduct these studies to gather additional safety and efficacy data for the drug.

(d) RISK EVALUATION AND MITIGATION STRATEGIES (REMS): REMS programs are designed to ensure the safe and appropriate use of the drug by integrating additional safety measures such as patient education, restricted distribution, or monitoring requirements.

(e) PHARMACOVIGILANCE SYSTEMS: This involves ongoing surveillance, data collection, analysis, and signal detection to identify any potential safety concerns promptly.

(f) COMPLIANCE AUDITS AND INSPECTIONS: These may be conducted by regulatory authorities to ensure that pharmaceutical companies are adhering to regulatory requirements.

MARKETING STRATEGIES

Marketing strategies for the launch of a new drug are crucial to ensure its successful introduction into the market and to reach the target audience.

1.MARKET RESEARCH:

(a) TARGET MARKET ANALYSIS: This involves identifying the patient population, demographics, and specific medical conditions like the drug addresses.

(b) COMPETITIVE ANALYSIS: It helps in understanding the strengths and weaknesses of competitors, differentiating the new drug, and positioning it effectively.

(b) DATA SOURCES: Electronic health records (EHRs), claims databases, national health registries, and disease-specific databases.

(c) PATIENT POPULATION: The inclusion of diverse patient populations allows for a better understanding of the drug's effectiveness, safety, and generalizability to different patient subgroups.

(d) EXPOSURE ASSESSMENT: Include the dose, duration, and frequency of drug use.

(c) CONSUMER INSIGHTS: This can be done through surveys, interviews, focus groups, and online research.

(d) AWARENESS AND PERCEPTION STUDIES: This can be done through surveys and interviews to gauge the level of awareness, knowledge, and potential barriers to adoption.

2. TARGET AUDIENCE IDENTIFICATION:

(a) PATIENT POPULATION: Start by understanding the medical condition that the new drug addresses and identify the specific patient population affected by the condition.

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

(b) PATIENT SEGMENTATION: This can include factors such as disease severity, treatment history, lifestyle preferences, or other relevant characteristics.

(c) HEALTHCARE PROFESSIONALS: This could include physicians, specialists, nurses, pharmacists, or other healthcare providers who have a significant influence on treatment decisions.
(b) VISUAL IDENTITY: Designing a visually appealing and recognizable logo and packaging that aligns with the drug's purpose, target audience, and overall brand positioning.

(c) REGULATORY COMPLIANCE: Ensuring that all branding elements adhere to regulatory guidelines and requirements specific to the pharmaceutical industry.

(d) VALUE PROPOSITION: Clearly articulating the benefits and advantages of the drug compared to existing treatments. Highlighting its efficacy, safety, mode of action, and any other differentiating factors.

(e) LONG-TERM RELATIONSHIP BUILDING: Develop strategies to build long-term relationships with healthcare professionals, patients, and stakeholders. This may involve ongoing educational programs, patient support initiatives, or collaborations with medical associations.

(f) COMMUNICATION CHANNELS: This may include a mix of traditional and digital marketing platforms such as medical journals, conferences,

5. MULTICHANNEL MARKETING:
(a) TARGET AUDIENCE ANALYSIS: Identify the target audience for the new drug, such as healthcare professionals, patients, caregivers, or other stakeholders.

(b) INTEGRATION AND CONSISTENCY: Ensure consistency in branding, messaging, and visual identity across all channels. Integrate marketing efforts across channels to provide a seamless and unified experience for the target audience.

(c) DIGITAL CHANNELS: Create a dedicated website that provides comprehensive information about the new drug, including its benefits, mechanism of action, dosing instructions, safety information, and frequently asked questions.

3. BRANDING AND MESSAGING:
(a) BRAND NAME: Developing a distinctive and memorable brand name for the drug is essential. It should be easy to pronounce, spell, and remember, while also complying with regulatory guidelines.

online advertising, social media, and healthcare professional networks.

4. KEY OPINION LEADER (KOL) ENGAGEMENT:
(a) IDENTIFICATION AND SELECTION: Conduct research and analysis to identify KOLs who have expertise and influence in the therapeutic area relevant to the new drug. Consider their professional reputation, publication record, speaking engagements, social presence, and relationship with other thought leaders.

(b) ENGAGEMENT STRATEGIES: Establish and nurture relationships with KOLs through various means, such as face-to-face meetings, conferences, advisory boards, and social media interactions. It is essential to demonstrate genuine interest in their work and seek their insights and perspectives.

(c) LONG-TERM RELATIONSHIP MANAGEMENT: Maintain regular and open lines of communication with KOLs to keep updated on new developments, clinical data and relevant research. This ensures their ongoing engagement and support for the new drug.
(d) TRADITIONAL CHANNELS: Place advertisements in medical journals, magazines, or newspapers that are read by healthcare professionals.

6. MEDICAL EDUCATION PROGRAMS:
(a) PURPOSE: To educate healthcare professionals such as physicians, pharmacists and nurses, about the benefits, risks and appropriate prescribing practices of the new drug.

(b) TARGET AUDIENCE: It includes healthcare professionals involved in prescribing, administering, or managing patients using the new drug.

(c) CONTENT DEVELOPMENT: It focuses on providing evidence-based information, including clinical trial data, mechanism of action, dosing

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

guidelines, safety profiles, potential drug interactions and patient selection criteria.

7. PATIENT EDUCATION AND SUPPORT:
(a) PURPOSE: To provide patients with comprehensive information about their medical
(c) CONTENT DEVELOPMENT: The content may include brochures, pamphlets, websites, videos, interactive tools, and other educational materials.

(d) MULTICHANNEL APPROACH: This may include digital platforms, websites, mobile applications, social media, patient support groups, direct mail, and healthcare provider office.

8. POST-LAUNCH TRACKING AND EVALUATION:
(a) DEFINE OBJECTIVES: These objectives can include market share, sales volume, customer awareness, physician adoption, or patient adherence.

(b) DATA COLLECTION: This can include sales data, prescription volume, market research surveys,

ANALYSIS OF SUCCESSFUL DRUG LAUNCHES

Analysing successful drug launches can provide valuable insights into effective strategies for launching and increasing the sales of a new drug. While I cannot provide real-time data or specific case studies beyond my knowledge cut-off date in September 2021, I can provide you with a general framework for analysing successful drug launches and the strategies that contribute to their success. Here are some key factors to consider:

1.MARKET RESEARCH:
Successful drug launches begin with thorough market research. This involves understanding the target patient population, unmet medical needs, competitive landscape, and key stakeholders. Gathering insights about patient demographics, treatment patterns, and physician preferences helps in designing effective strategies tailored to the specific market dynamics.

2. TARGETED POSITIONING:
Positioning the new drug effectively is crucial for differentiation and market penetration. Analysing successful drug launches involves examining how or educational initiatives helps in gaining expert endorsement, building physician confidence, and expanding the drug's reach.

condition, the new drug, its benefits, potential side effects, and proper usage.

(b) TARGET AUDIENCE: It may include patients, their caregivers, and their families.

social media analytics, website traffic, and other relevant metrics.

(c) MEASURE BRAND AWARENESS: This can be done through surveys, focus groups, or online sentiment analysis to understand brand recognition, recall, and overall sentiment.

(d) EVALUATE PHYSICIAN ADOPTION: This can involve tracking prescription data, conducting physician surveys, or utilizing physician feedback mechanisms.

(e) CONTINUOUS MONITORING: This allows for timely identification of emerging trends, market shifts, or competitive challenges that may require adjustments in marketing strategies.

the drug was positioned to address the unmet needs of patients or offer distinct advantages over existing treatments. This includes identifying unique selling points such as improved efficacy, safety, convenience, or cost-effectiveness, and clearly communicating them to healthcare professionals and patients.

3.REGULATORY COMPLIANCE:
Compliance with regulatory requirements is essential for a successful drug launch. Analysing successful launches involves examining how companies navigated the regulatory landscape, gained necessary approvals and adhered to labelling and promotional guidelines. Ensuring compliance minimizes regulatory risks and helps to maintain trust and credibility with stakeholders.

4.KEY OPINION LEADER (KOL) ENGAGEMENT:
Engaging with influential KOLs is a common strategy in successful drug launches. Analysing such launches involves studying how companies identified and engaged with KOLs who had expertise in the therapeutic area. Collaborating with KOLs for clinical trials, advisory boards,
5.MARKETING AND COMMUNICATION STRATEGIES:
Effective marketing and communication strategies play a pivotal role in successful drug launches.

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

Analysing these launches involves evaluating the use of various channels such as digital marketing, medical conferences, journal publications, and direct-to-consumer advertising (where permitted). Assessing the messaging, content, and timing of these strategies helps in understanding how the companies effectively reached and engaged with their target audience.

6. PATIENT EDUCATION AND SUPPORT:
Providing comprehensive patient education and support programs contributes to the success of drug launches. Analysing successful launches involves examining how the companies designed initiatives to educate patients about the disease, treatment options, and the benefits of the new drug. Patient support programs that provide access, affordability assistance, and adherence support help in increasing patient acceptance and satisfaction.

7. SALES FORCE EFFECTIVENESS:
A well-trained and motivated sales force is crucial for the success of a drug launch. Analysing successful launches involves assessing how companies trained their sales representatives on the drug's features, benefits, and clinical evidence. Companies that invest in sales force effectiveness by providing robust product training, effective sales tools, and incentive programs are more likely to achieve higher sales.

8. POST-LAUNCH EVALUATION AND ADAPTATION:
Successful drug launches involve continuous evaluation and adaptation based on real-world data and feedback. Analysing these launches includes studying how companies monitored post-launch performance, analysed market trends, and adjusted their strategies accordingly. This iterative process ensures ongoing success and allows for refinement and optimization of marketing and sales efforts.

FACTORS CONTRIBUTING TO SUCCESS
Several factors contribute to the success of launching and increasing the sales of a new drug. These factors encompass various aspects of product development, marketing, sales, and customer engagement. Here are some key factors that play a significant role:

1.EFFICACY AND SAFETY:
The fundamental factor contributing to the success of a new drug is its efficacy and safety profile. Clinical trials and scientific evidence demonstrating the drug's effectiveness in treating the targeted condition, along with a favourable safety profile, build confidence among healthcare professionals and patients.

2. UNMET MEDICAL NEED:
Addressing an unmet medical need provides a competitive advantage and increases the chances of success. If a new drug offers significant improvements over existing treatments or targets a condition for which there are limited or no effective options, it has a higher likelihood of gaining market share.

channels such as digital marketing, traditional advertising, medical conferences, and peer-reviewed publications.

3.TARGET MARKET ANALYSIS:
Conducting a thorough analysis of the target market is essential for developing effective marketing and sales strategies. This includes evaluating patient demographics, disease prevalence, treatment patterns, and healthcare infrastructure. Understanding the market dynamics helps in identifying the target audience, tailoring messaging, and determining the most suitable channels for reaching and engaging with healthcare professionals and patients.

4.DIFFERENTIATION AND POSITIONING:
Differentiating the new drug from competitors and effectively positioning it in the market are crucial for success. Highlighting unique features such as improved efficacy, safety, convenience, or cost-effectiveness, helps the drug stand out.

5.COMPREHENSIVE MARKETING AND COMMUNICATION STRATEGIES:
Implementing robust marketing and communication strategies is vital for raising awareness and driving sales. This includes developing targeted promotional campaigns, utilizing various

6. PHYSICIAN AND KEY OPINION LEADER(KOL) ENGAGEMENT:
Engaging healthcare professionals and key opinion leaders is critical for the success of a new drug

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

launch. Building relationships with physicians, conducting medical education programs, and involving KOLs in clinical trials and advisory boards help in gaining expert endorsement and increasing preparation rates.

7. PATIENT EDUCATION AND SUPPORT:
Educational and supporting patients is crucial for successful drug launches. Providing clear and accurate information about the drug's benefits, usage, and potential side effects helps patients make informed decisions.

8. SALES FORCE EFFECTIVENESS:
A well-trained and motivated sales force plays a vital role in driving the sales of a new drug. Providing comprehensive product training, equipping sales representatives with effective sales tools, and incentivizing their performance help maximize the reach and impact of the sales team. Regular monitoring, feedback, and support ensure continuous improvement and adaptation to market dynamics.

9. MARKET ACCESS AND REIMBURSEMENT:
Securing favourable market access and reimbursement is crucial for achieving commercial success. Forming strategic partnerships, negotiating favourable pricing, and addressing market access barriers contribute to increased sales opportunities.

10. POST-LAUNCH MONITORING AND ADAPTATION:
Continuous evaluation of market performance, monitoring of real-world data, and adaptation of strategies based on insights are essential for sustained success. Analysing sales data, patient feedback, market trends, and competitive landscape helps in identifying areas for improvement and refining marketing and sales approaches over time.

SURVEY QUESTIONS ON LAUNCHING AND INCREASING THE SALES OF A NEW DRUG

Q1. How familiar are you with the process of launching a new drug in the market?
a. Very familiar
b. Somewhat familiar
c. Not familiar at all

Q2. In your opinion, what are the key factors that contribute to the successful launch of a new drug?
a. Effective marketing and promotional strategies
b. Strong relationships with healthcare professionals
c. Pricing and reimbursement strategy
d. Patient education and engagement

Q3. Which marketing and promotional strategies do you believe are most effective in increasing the sales of a new drug?
a. Direct-to-consumer advertising
c. Involving KOLs in advisory boards and research studies
d. Finance incentives and compensation

Q6. How much do you think pricing and reimbursement strategy impact the market penetration and sales of a new drug?
a. Significantly
b. Moderately
c. Minimally

Q7. Which channels and methods do you find most effective for reaching and engaging target patient populations to drive the uptake of a new drug?
b. Targeted advertising to healthcare professionals
c. Online marketing and social media campaigns
d. Physician education programs and seminars
e. Collaborations with patient advocacy groups

Q4. How important do you think physician education and engagement are for the successful adoption and sales of a new drug?
a. Very important
b. Somewhat important
c. Not important at all

Q5. In your experience, what are the critical factors in establishing and maintaining strong relationships with key opinion leaders (KOLs) to drive the sales of a new drug?
a. Providing scientific and clinical data
b. Offering ongoing medical education and support

a. Healthcare provider recommendations
b. Online patient communities and forums
c. Direct-to-patient advertising
d. Education materials and brochures in clinics
e. Support programs and patient assistance initiatives

Q8. How important do you believe market segmentation and targeting are for the success of a new drug launch and sales growth?
a. Very important
b. Somewhat important
c. Not important at all

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

Q9. In your opinion, what role do digital marketing and online platforms play in the promotion and sales of a new drug?
a. Essential role
b. Significant role
c. Minimal role

c. Ineffective

Q11. How influential do you believe the key opinion leaders (KOLs) is in driving the adoption and sales of a new drug?
a. Extremely influential
b. Moderately influential
c. Not influential at all

Q12. How important do you think real-world evidence and post-marketing studies are in supporting the sales and market growth of a new drug?
a. Very important
b. Somewhat important
c. Not important at all

Q13. How much impact do you think patient testimonials and success stories have on the sales and acceptance of a new drug?
Q16. How important do you believe collaboration and partnerships with other healthcare stakeholders (Ex: hospitals, pharmacies, insurance providers) are in facilitating the launch and sales of a new drug?
a. Very important
b. Moderately important
c. Not important at all

Q17. How satisfied are you with the current regulatory environment and processes related to new drug launches and sales?
a. Very satisfied
b. Moderately satisfied
c. Not satisfied at all

Q18. How frequently do you believe pharmaceutical companies should engage in post-launch monitoring and evaluation to assess the effectiveness of their strategies and make necessary adjustments?

Q10. How important do you think the current methods of communicating the value and benefits of a new drug are to healthcare professionals, payers and patients?
a. Highly effective
b. Moderately effective

a. Significant impact
b. Moderate impact
c. Negligible impact

Q14. How well do you think pharmaceutical companies utilize data analytics and market research to inform their strategies for launching and increasing the sales of a new drug?
a. Very well
b. Moderately well
c. Poorly

Q15. Which factors do you consider when evaluating the potential of a new drug to achieve successful market entry and sales growth?
a. Efficacy and safety profile
b. Competitive landscape and market saturation
c. Pricing and reimbursement potential
d. Target patient population size and unmet needs

a. Regularly (Ex: Quarterly)
b. Occasionally (Ex: Annually)
c. Infrequently (Ex: Once every few years)

Q19. How confident are you in the ability of effective marketing and sales strategies to drive the success of a new drug in the market?
a. Very confident
b. Moderately confident
c. Not confident at all

Q20. What channels or sources of information do you trust the most when it comes to learning about new medications?
a. Healthcare professionals
b. Medicine websites
c. Friends or family members
d. Pharmaceutics company websites
e. Online forums

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

III. RESULTS AND DISCUSSIONS

1. How familiar are you with the process of launching a new drug in the market?
85 responses

2. In your opinion, what are the key factors that contribute to the successful launch of a new drug?
84 responses

3. Which marketing and promotional strategies do you believe are most effective in increasing the sales of a new drug?
83 responses

4. How important do you think physician education and engagement are for the successful adoption and sales of a new drug?
83 responses

5. In your experience, what are the critical factors in establishing and maintaining strong relationships with key opinion leaders (KOLs) to drive the sales of a new drug?
80 responses

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

6. How much do you think pricing and reimbursement strategy impact the market penetration and sales of a new drug?
81 responses



7. Which channels and methods do you find most effective for reaching and engaging target patient populations to drive the uptake of a new drug?
81 responses



8. How important do you believe market segmentation and targeting are for the success of a new drug launch and sales growth?
80 responses



International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

9. In your opinion, what role do digital marketing and online platforms play in the promotion and sales of a new drug?
81 responses



10. How effective do you think the current methods of communicating the value and benefits of a new drug are to healthcare professionals, payers and patients?
81 responses

11. How influential do you believe the key opinion leaders (KOLs) is in driving the adoption and sales of a new drug?
81 responses

12. How important do you think real-world evidence and post marketing studies are in supporting the sales and market growth of a new drug?
80 responses

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

13. How much impact do you think patient testimonials and success stories have on the sales and acceptance of a new drug?
81 responses



14. How well do you think pharmaceutical companies utilize data analytics and market research to inform their strategies for launching and increasing the sales of a new drug?
80 responses

15. Which factors do you consider when evaluating the potential of a new drug to achieve successful market entry and sales growth?
81 responses

16. How important do you believe collaboration and partnerships with other healthcare stakeholders (Ex: Hospitals, pharmacies, insurance providers) are in facilitating the launch and sales of a new drug?
80 responses

17. How satisfied are you with the current regulatory environment and processes related to new drug launches and sales?
81 responses

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

18. How frequently do you believe pharmaceutical companies should engage in post-launch monitoring and evaluation to assess the effectiven... their strategies and make necessary adjustments?
80 responses

19. How confident are you in the ability of effective marketing and sales strategies to drive the success of a new drug in the market?
81 responses

20. What channels or sources of information do you trust the most when it comes to learning about new medications?
81 responses

RESULT ANALYSIS: The survey is done with 87 people and result analysis concluded that the majority of people concluded are aware with the process of launching and increasing the sales of a new drug and trust them. It shows that effective marketing and promotional strategies is the main factor that contribute to the successful launch of a new drug. Online marketing and social campaigns are most effective in increasing the marketing and promotional strategies. So, it was concluded that increasing the sales of a new drug mainly depends on efficacy and safety profile and pricing and reimbursement strategy.

Launching and increasing the sales of a new drug require careful planning and effective strategies. In this section, we will discuss some key results and discussions related to these strategies:

1. MARKET RESEARCH: Conducting thorough market research is essential to understand the target audience, competition, and market dynamics. It helps in identifying the potential demand for the new drug and determining the most effective marketing strategies.

2. REGULATORY APPROVAL: Successfully obtaining regulatory approval from the relevant authorities is crucial before launching a new drug. This process involves demonstrating the drug's safety, efficacy, and quality through clinical trials and other supporting data.

3. POSITIONING AND DIFFERENTIATION: Developing a clear positioning strategy and highlighting the unique selling points of the drug are important for differentiating it from competitors. This can be achieved by emphasizing specific benefits, such as superior efficacy, safety profile, convenience, or cost-effectiveness.

4. TARGETED MARKETING CAMPAIGNS: Creating targeted marketing campaigns tailored to

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1736-1758 www.ijprajournal.com ISSN: 2456-4494

specific customer segments can help to reach the right audience effectively. This may involve in utilizing various marketing channels including digital platforms, healthcare professionals, patient advocacy groups, and direct-to-consumer advertising.

IV. CONCLUSION

Certainly! Here are more detailed points to consider in the conclusion for launching and increasing the sales of a new drug:

1. MARKET DIFFERENTIATION: A thorough understanding of the competitive landscape is crucial for effectively positioning the new drug in the market. Highlighting its unique features such as improved efficacy, reduced side effects, or convenience, helps differentiate it from existing treatments and attracts the attention of healthcare professionals and patients.

2. MULTICHANNEL MARKETING CAMPAIGNS: Utilizing a mix of traditional and digital marketing channels ensures a wider reach and maximizes the impact of promotional efforts. This may include targeted advertising in medical journals, online platforms, social media and search engine marketing.

3. PATIENT-CENTRIC APPROACH: Understanding the patient needs and providing support beyond the drug itself can significantly impact on sales growth.

4. PRICING AND REIMBURSEMENT OPTIMIZATION: Developing a well-defined pricing strategy, considering factors such as cost-effectiveness, market dynamics, and payer requirements is crucial for successful market access. Collaborating with payers and reimbursement agencies to secure favourable coverage and reimbursement for the drug is essential for driving sales growth.

5. KEY OPINION LEADER (KOL) ENGAGEMENT: Collaborating with respected healthcare professionals and KOLs who specialize in the therapeutic area of the new drug can significantly impact its success.

5. CONTINUOUS IMPROVEMENT: Launching a new drug is an ongoing process that requires continuous evaluation and optimization. Regularly reviewing and refining the marketing strategy, sales performance, and customer feedback enables the identification of areas for improvement and the implementation of corrective measures. Adapting to market dynamics and staying abreast of emerging trends ensures sustained sales growth and long-term success.

REFERENCES

[1]. Lanjouw, J.O.: The introduction of pharmaceutical product patent in India. Oxford Electronic Journal of Intellectual Property Rights 07/99 (1999).
[2]. Lanjouw, J.O.: Intellectual Property and the Availability of Pharmaceuticals in Poor Countries. Working paper no.5 Centre for Global Development (2002).
[3]. Bhaduri, S., Ray, A.S.: A game theoretic model of drug launch in India. Health Econ. Policy Law 1(1), (2006).
[4]. Davis, H. 2003. The licensing of medicines, UK Medicines Information, Liverpool, United Kingdom.
[5]. Cullen, R.: Pharmaceuticals inter-country diffusion. Manag. De-cis. Econ. 4(2), (1983) Danzon, P.M., Wang, Y.R., Wang, L.: The impact of price regulation on launch delay of new drugs—evidence from twenty-five major markets in the 1990s, 14(2005).
[6]. Cook, A.C. 2006. Forecasting for the Pharmaceutical Industry: Models for New Product and In-Market Forecasting and How to Use Them, Gower Publishing Limited, Hampshire, England.
[7]. Danzon, P. M., & Epstein, A. J. (2009). Effects of regulation on drug launch and pricing in interdependent markets. NBER Working Paper 10536. Retrieved from http://www.nber. org/papers/w14041.
[8]. Danzon, P. M., & Furukawa, M. F. (2003). Prices and availability of pharmaceuticals: Evidence from nine countries. Health Affairs Web Exclusive, October 2003.
[9]. Retrieved fromhttp://content.healthaffairs.org/cgi/content/full/hlthaff.w3.521v1/DC1. doi:10.1377/hlthaff.w3.521.
[10]. Danzon, P. M., & Furukawa, M. F. (2008). International prices and availability of pharmaceuticals in 2005. Health Affairs, 27(1), doi:10.1377/hlthaff.27.1.221.
[11]. Danzon, P. M., Wang, Y. R., & Wang, L. (2005). The impact of price regulation on the launch delay of new drugs: A study of twenty-five major markets in 1990s.